Overview

• The FTC launched a 60-day comment period on alleged false or unsupported claims about gender-affirming care for minors, inviting submissions through September 26 on Regulations.gov.
• Investigators are evaluating whether providers violated consumer protection laws by omitting material risks or overstating benefits of youth transition treatments.
• DOJ Chief of Staff Chad Mizelle confirmed that nearly 20 subpoenas have been issued to clinics and drug manufacturers in related health care fraud and false-statements inquiries.
• Major health systems, including Kaiser Permanente and D.C. Children’s National Hospital, have paused or halted gender-affirming procedures and prescriptions for minors following federal probes.
• A July FTC workshop featuring detransitioners, parents and medical whistleblowers shaped the inquiry’s focus on consumer harm and deceptive trade practices.